Login to Your Account

Nascent deal brings preclinical-stage cancer drug to China's Hisun

By Pearl Liu
Staff Writer

Friday, July 22, 2016

HONG KONG – Looking to continue morphing from a maker of APIs to a key biologic drug developer and manufacturer, Zhejiang Hisun Pharmaceutical Co. Ltd. has bought the rights to a targeted therapy for epithelioma in China from Nascent Biotech Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription